Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever investment

This article was originally published in The Rose Sheet

Executive Summary

Unilever dedicating nearly $170 mil. to corporate ventures to build business opportunities in food and home and personal care, company announces Sept. 30. Majority of the funding - nearly $100 mil. - will be dedicated to Langholm Capital Partners Fund, which will target investments in mid-market European consumer-facing businesses, Unilever says. Additionally, firm will invest almost $40 mil. over three years in Unilever Ventures, "an early stage business development fund supporting early stage business ideas," company says. Nearly $30 mil. will be used to identify and invest in technology-based funds and start up companies via Unilever Technology Ventures. Goal is to "enhance the scope and quality of Unilever's own R&D activities by exploiting new technologies," company says, noting areas of investment will include genomics, advanced bioscience, advanced materials science and nanotechnology...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel